Provention Bio to Resubmit Teplizumab License App, Shares Rise 12%
January 27 2022 - 5:53PM
Dow Jones News
By Stephen Nakrosis
Shares of biopharmaceutical company Provention Bio Inc. are
higher in Thursday's late-trading session, after the company said
it intends to resubmit the teplizumab Biologics License
Application, following a meeting with the U.S. Food and Drug
Administration.
The company said teplizumab is being developed to delay clinical
type 1 diabetes in at-risk individuals.
"We look forward to re-submitting the BLA as soon as possible
and facilitating the FDA's review and decision-making," said
Ashleigh Palmer, co-founder and chief executive.
At 5:08 p.m. ET, shares were trading 12.65% higher at $3.83.
The stock finished the day's regular-trading session at a
52-week low of $3.40.
The company scheduled a conference for Jan. 28 at 8 a.m. ET.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
January 27, 2022 17:38 ET (22:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Sep 2023 to Sep 2024